• Landmark collaboration between the Serum Institute of India, Gavi, and Bill & Melinda Gates Foundation
• The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide atrisk funding of US$150 million to Gavi, which will be used to support the SII to manufacture the potential vaccine candidates
• Vaccines will be priced at maximum $3 per dose and made available to the 92 countries
Mumbai, NFAPost: Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, has entered into a new landmark partnership with Gavi, The Vaccine Alliance and the Bill & Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries (LMICs).
The collaboration will provide upfront capital to SII to help them increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO prequalification, doses can be produced at scale for distribution to India and LMIC as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.
The funding will support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification.
SII has set an affordable ceiling price of US$ 3 per dose. The arrangement also provides an option to secure additional doses if the vaccines pillar of the ACT Accelerator sees a need for it.
Unimaginable uncertainity
“In an attempt to make our fight against COVID-19 stronger and all-embracing; SII has partnered with Gavi and the Bill & Melinda Gates Foundation to advance the manufacturing and delivery of up to 100 million doses of future COVID vaccines for India and low and middle income countries in 2021,” said Adar Poonawalla, CEO of Serum Institute of India.
“The rampant spread of the virus has rendered the entire world in an unimaginable halt of uncertainty. And to ensure maximum immunization coverage and contain the pandemic, it is important to make sure that the most remote and poorest countries of the world have access to affordable cure and preventive measures. Through this association, we seek
to ramp up our constant efforts to save the lives of millions of people from this dreadful disease.”
SII shares a long history of successful partnerships with Gavi and pharmaceutical companies to manufacture vaccines that protect against meningitis, severe diarrhoea, pneumonia and measles. This collaboration further underscores India’s proven-track record in developing safe and quality vaccines.
Cost-effective vaccine
Commenting on the collaboration, Department of Biotechnology Secretary Dr Renu Swarup said India has a proven track record of manufacturing safe and cost-effective vaccines not only for India, but for the world.
“Over the last decade, the Government of India has encouraged innovation and supported the Indian vaccine industry to manufacture high quality, affordable indigenous tools and products to benefit India and the world. We are very happy to see SII enter this global partnership to respond to the global health crisis posed by Covid-19,” said Department of Biotechnology Secretary Dr Renu Swarup.
Dr Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), commented that India’s has demonstrated consistent capability in delivering on low-cost and high-quality medical research, while also maintaining technical and scientific rigour.
“ICMR is deeply supportive of our cutting edge vaccine research and manufacturing prowess, of which SII is one prominent example. This partnership signifies yet another step in India’s efforts to bolster the fight against this global pandemic,” said Director General of Indian Council of Medical Research (ICMR) Dr Balram Bhargava.
Mutual collaboration
The Gavi COVAX AMC, which is currently seeking at least $ 2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine doses. Last week the Gavi Board agreed the final list of 92 countries that will be supported by the AMC.
Under the new collaboration, AstraZeneca’s candidate vaccine, if successful, will be available to 57 Gavi-eligible countries. Novavax’s candidate, if successful, will be available to all 92 countries supported by the AMC.
The collaboration between Gavi, SII, and the Gates Foundation supports the efforts of the ACT Accelerator’s vaccines pillar, also known as COVAX, co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to accelerate the development of Covid-19 vaccines and ensure rapid, global access to them.
Decisions around investment in manufacturing are taken in close collaboration between these three lead organisations of
the COVAX pillar.
Technology platform
Under the COVAX umbrella, Gavi is leading the COVAX Facility, which provides governments with the opportunity to benefit from a large portfolio of Covid-19 candidate vaccines using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand.
The Facility is reinforced by the AMC which provides funding for vaccines for lower income countries.
The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of $150 million to Gavi, which will be used to support the Serum Institute of India to manufacture potential vaccine candidates, and for future procurement of vaccines for low- and middle-income countries via Gavi’s COVAX AMC.
The deal builds on a Memorandum of Understanding between AstraZeneca and Gavi, announced in June, which will guarantee 300 million doses of AstraZeneca’s candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification. These two deals can help guarantee access to early doses for the most vulnerable on a truly global scale.
Serum Institute of India (SIIPL)
Driven by the philanthropic philosophy of affordable vaccines; Serum Institute of India Pvt, Ltd. (SIIPL) is the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses), supplying the world’s cheapest and WHO accredited vaccines to as many as 170 countries.
It was founded in 1966 with the aim of manufacturing lifesaving immunobiological drugs including vaccines worldwide. With a strong commitment towards global health, the institute’s objective has been proliferated by bringing down the prices of newer vaccines such as such as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines.
SII is credited with bringing world-class technology to India, through its state-of-the-art equipped multifunctional production facility in Manjri, Pune. In association with Zipline and government agencies, the company succeeded in transforming emergency medicine and critical care along with spearheading the race of vaccine development against the Covid-19 pandemic.
